专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007090584A1 MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE 审中-公开
标题翻译：改进的凝血因子维拉与延伸的生命
公开(公告)号：WO2007090584A1
公开(公告)日：2007-08-16
申请号：PCT/EP2007/000937
申请日：2007-02-03
申请人： ZLB BEHRING GMBH , WEIMER, Thomas , SCHULTE, Stefan , KRONTHALER, Ulrich , LANG, Wiegand , LIEBING, Uwe , WORMSBÄCHER, Wilfried
发明人： WEIMER, Thomas , SCHULTE, Stefan , KRONTHALER, Ulrich , LANG, Wiegand , LIEBING, Uwe , WORMSBÄCHER, Wilfried
IPC分类号： C12N15/62 , C07K14/76 , C12N9/64 , C07K19/00 , A61K38/48
CPC分类号： A61K38/4846 , A61K9/0019 , A61K38/00 , A61K38/385 , C07K14/76 , C07K2319/00 , C07K2319/31 , C12N9/6437 , C12N9/96 , C12N15/62 , C12Y304/21021
摘要： The present invention relates to the fields of Factor VII (FVII) and Factor Vila (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor Vila and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
摘要翻译：本发明涉及因子VII（FVII）和因子VIIa（FVIIa）白蛋白连接多肽的领域。更具体地，本发明涉及编码人因子VII和因子VIIa的cDNA序列和与编码人血清白蛋白的cDNA遗传融合的衍生物，其可以通过寡核苷酸连接，所述寡核苷酸编码插入的肽接头体，所述衍生物表现出改善的稳定性和延伸的功能血浆半衰期，含有这些cDNA序列的重组表达载体，用这种重组表达载体转化的宿主细胞，确实具有未修饰的野生型蛋白的生物活性但具有改善的稳定性和延长的保存期限的重组多肽和衍生物制备这些重组蛋白及其衍生物。本发明还涵盖用于人基因治疗的转移载体，其包含这种修饰的DNA序列。

2. 发明申请

WO2009156137A1 FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE 审中-公开
标题翻译：因子VIII，VON WILLEBRAND因子或其复合物与生殖健康生活息息相关
公开(公告)号：WO2009156137A1
公开(公告)日：2009-12-30
申请号：PCT/EP2009/004549
申请日：2009-06-24
申请人： CSL BEHRING GMBH , WEIMER, Thomas , SCHULTE, Stefan , METZNER, Hubert , KRONTHALER, Ulrich , LIND, Holger , LANG, Wiegand
发明人： WEIMER, Thomas , SCHULTE, Stefan , METZNER, Hubert , KRONTHALER, Ulrich , LIND, Holger , LANG, Wiegand
IPC分类号： C12N15/12 , C07K14/755 , A61K38/37 , C12N5/10 , G01N33/86
CPC分类号： C07K14/76 , A61K38/00 , C07K14/755 , C07K2319/31
摘要： The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.
摘要翻译：本发明涉及编码凝血因子VIII（FVIII）和von Willebrand因子（VWF）的修饰的核酸序列及其复合物及其衍生物，含有此类核酸序列的重组表达载体，用这种重组表达转化的宿主细胞载体，重组多肽和由所述核酸序列编码的衍生物，所述重组多肽和衍生物与未修饰的野生型蛋白质相比具有生物活性以及延长的体内半衰期和/或改善的体内恢复。本发明还涉及导致表达产量提高的相应FVIII序列。本发明还涉及制备这些重组蛋白及其衍生物的方法。本发明还涉及用于人基因治疗的转移载体，其包含这种修饰的核酸序列。

3. 发明申请

WO2008098720A1 THERAPEUTIC APPLICATION OF KAZAL-TYPE SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：卡氏型丝氨酸蛋白酶抑制剂的治疗应用
公开(公告)号：WO2008098720A1
公开(公告)日：2008-08-21
申请号：PCT/EP2008/001009
申请日：2008-02-11
申请人： CSL BEHRING GMBH , SCHULTE, Stefan , KRONTHALER, Ulrich , SCHMIDBAUER, Stefan , WEIMER, Thomas , HOFMANN, Kay
发明人： SCHULTE, Stefan , KRONTHALER, Ulrich , SCHMIDBAUER, Stefan , WEIMER, Thomas , HOFMANN, Kay
IPC分类号： A61K38/57 , A61P7/02 , C07K14/81
CPC分类号： C07K14/8135 , A61K38/00 , A61K47/64 , A61K47/643
摘要： The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type serine protease inhibitor lnfestin or domains thereof or modified Kazal-type serine protease inhibitors based on lnfestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. In particular the present invention relates to the use of said Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors, in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i. e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis.
摘要翻译：本发明的主题在最一般的方面是基于伊斯匹林同系物的Kazal型丝氨酸蛋白酶抑制剂腹膜内酯或其结构域或修饰的Kazal型丝氨酸蛋白酶抑制剂的治疗应用，其阻止形成和/或稳定化通过干扰参与所谓的内在凝血途径的激活的蛋白质的三维动脉或静脉血栓。特别地，本发明涉及所述Kazal型丝氨酸蛋白酶抑制剂或其片段或修饰的Kazal型丝氨酸蛋白酶抑制剂在治疗或预防与动脉血栓形成相关的病症或障碍中的用途，即中风或心肌梗塞，炎症，补体激活，纤维蛋白溶解，血管生成和/或与病理激肽形成相关的疾病，例如低渗休克，包括遗传性血管性水肿，细菌感染，关节炎，胰腺炎或关节痛风的水肿，弥散性内皮内凝血（DIC）和败血症。

4. 发明申请

WO2011020866A2 ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS 审中-公开
标题翻译：治疗中非侵入性治疗的ALBUMIN融合凝血因子和BLEEDING疾病的预防治疗
公开(公告)号：WO2011020866A2
公开(公告)日：2011-02-24
申请号：PCT/EP2010/062069
申请日：2010-08-18
申请人： CSL BEHRING GmbH , KRONTHALER, Ulrich
发明人： KRONTHALER, Ulrich
IPC分类号： A61K47/48 , A61K9/00 , A61P7/04 , C07K14/745 , C07K14/75 , C07K14/755 , C07K14/765 , C12N15/62 , A61K38/36
CPC分类号： C12N9/644 , A61K9/0019 , A61K38/37 , A61K38/4833 , A61K38/4846 , A61K47/643 , C07K14/745 , C07K14/755 , C07K2319/31 , C12N9/6437 , C12Y304/21021 , C12Y304/21022
摘要： The present invention relates to pharmaceutical preparations comprising albumin- fused coagulation factors for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders and to a method for increasing the in- vivo recovery after non-intravenous administration of a coagulation factor by fusing it to albumin.
摘要翻译：本发明涉及药物制剂，其包含用于非静脉内施用的白蛋白融合凝血因子，用于治疗出血性疾病的治疗和预防性治疗以及通过融合非静脉内施用凝血因子后增加体内恢复的方法它到白蛋白。

5. 发明申请

WO2009129980A1 METHOD FOR THE PREVENTION AND TREATMENT OF CANCER BY INHIBITION OF GPVI 审中-公开
标题翻译：通过抑制GPVI预防和治疗癌症的方法
公开(公告)号：WO2009129980A1
公开(公告)日：2009-10-29
申请号：PCT/EP2009/002864
申请日：2009-04-20
申请人： CSL BEHRING GMBH , KRONTHALER, Ulrich , Nieswandt, Bernhard
发明人： KRONTHALER, Ulrich , Nieswandt, Bernhard
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/3053
摘要： The invention provides an inhibitor of GPVI for the prevention and or therapy of cancer and also the use of such an inhibitor of GPVI in the manufacture of a medicament for the prevention and/or therapy of cancer. A further aspect of the invention are pharmaceutical formulations comprising a GPVI inhibitor, which are suitable for the treatment of cancer, preferably for skin cancer, more preferably for melanoma, and most preferably for malignant cutaneous melanoma.
摘要翻译：本发明提供了用于预防和/或治疗癌症的GPVI抑制剂，以及GPVI抑制剂在制备用于预防和/或治疗癌症的药物中的用途。本发明的另一方面是包含GPVI抑制剂的药物制剂，其适用于治疗癌症，优选用于皮肤癌，更优选用于黑素瘤，最优选用于恶性皮肤黑素瘤。

6. 发明申请

WO2008151817A1 USE OF VWF STABILIZED FVIII PREPARATIONS AND OF VWF PREPARATIONS WITHOUT FVIII FOR EXTRAVASCULAR ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS 审中-公开
标题翻译：使用VWF稳定的FVIII制剂和VWF制剂，没有FVIII用于治疗和预防治疗疾病的治疗中的超声管理
公开(公告)号：WO2008151817A1
公开(公告)日：2008-12-18
申请号：PCT/EP2008/004770
申请日：2008-06-13
申请人： CSL BEHRING GMBH , KRONTHALER, Ulrich
发明人： KRONTHALER, Ulrich
IPC分类号： A61K38/37 , A61K38/36 , A61P7/04
CPC分类号： A61K38/36 , A61K38/27 , A61K38/37 , A61K2300/00
摘要： The present invention relates to the use of von Willebrand Factor (VWF) preparations or of a VWF preparation in combination with coagulation Factor VIII (FVIII) for extravascular administration in the therapy and prophylactic treatment of bleeding disorders.
摘要翻译：本发明涉及血管性血友病因子（VWF）制剂或VWF制剂与凝血因子VIII（FVIII）联合用于血管外给药的治疗和预防性治疗出血性疾病的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式